MedDataX Logo

A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors

NCT ID: NCT02279758

Last Updated: 2014-10-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Neuroendocrine tumors are rare but recent data showed a relevant increase in its incidence. The Mammalian Target of Rapamycin (mTOR), one of most important area of research, has demonstrated be a therapeutic target in these tumors. The metformin has demonstrate in preclinical studies having an antineoplastic action by inhibiting the mTOR pathway, and may be an alternative treatment for this disease.

Eligible patients for this study should have metastatic gastroenteropancreatic neuroendocrine tumors well differentiated (grade 1 or grade 2) and will be treated with metformin 850 mg every 12 hours, and each cycle will consist of 30 days. After 180 days of treatment the efficacy of metformin under the control of disease progression will be evaluated. As a secondary outcome the investigator will check the patient adherence to the treatment, the control of patient symptoms with functioning neuroendocrine tumor, and disease free survival. Also will be performed an analysis of immunohistochemical expression of mTOR pathway proteins of these patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Well-differentiated Neuroendocrine Tumors

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Neuroendocrine Tumors The Mammalian Target of Rapamycin (mTOR) metformin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

METFORMIN

850mg of metformin every 12 hours.

Group Type EXPERIMENTAL

Metformin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Metastatic well-differentiated neuroendocrine tumor grade 1 or 2 with histological confirmation;
* Performance status according to Eastern Cooperative Oncology Group (ECOG) 0 to 2;
* Able to take pills;
* Age ≥ 16 years;
* Ability to Provide Written Informed Consent;
* Adequate organ function;

Exclusion Criteria

* Patient with out of control severe hormonal syndrome;
* Diabetic patients under metformin treatment, or those who have received treatment with metformin within 3 months;
* Patient with hypersensitivity to biguanides, kidney or liver failure, or other conditions that predispose to lactic acidosis;
* History of severe clinical or psychiatric illness, that would prevent participation in the study by clinical judgment;
* Patients who participate in other protocol with experimental drugs;
* Patients under any kind of active infection;
* Patients who have received chemotherapy within 3 weeks;
* Patients pregnant or lactating;
* Diabetic patients who require higher dose of metformin 850mg x 2 daily;
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto do Cancer do Estado de São Paulo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

João Glasberg, MD

Role: PRINCIPAL_INVESTIGATOR

Instituto do Cancer do Estado de São Paulo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Instituto do Cancer do Estado de São Paulo

São Paulo, São Paulo, Brazil

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

João Glasberg, MD

Role: CONTACT

Phone: 55 11 38932000

Email: [email protected]

Rachel Riechelmann, MD

Role: CONTACT

Phone: 55 11 38932000

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

João Glasberg, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NP 515/2014

Identifier Type: -

Identifier Source: org_study_id